Существует ли «окно терапевтических возможностей» для тестостерон-заместительной терапии при возрастном гипогонадизме у мужчин?
- Авторы: Апетов С.С1, Апетова В.В1
-
Учреждения:
- ООО «Центр эндокринного здоровья»
- Выпуск: Том 29, № 6 (2022)
- Страницы: 47-56
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/321012
- DOI: https://doi.org/10.18565/pharmateca.2022.6.47-56
- ID: 321012
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
В статье обсуждаются вопросы сердечно-сосудистой безопасности тестостерон-заместительной терапии (ТЗТ) при возрастном андрогенном дефиците у мужчин. ТЗТ может усугублять сердечно-сосудистую патологию у некоторых пациентов с субоптимальными уровнями тестостерона. В целом риск ССС на фоне ТЗТ невелик. У мужчин наблюдаются индивидуальные различия в сроках наступления возрастного андрогенного дефицита, обусловленные главным образом половой конституцией. Соответственно, и скорость прогрессирования атеросклероза будет различаться у разных мужчин одного и того же возраста в зависимости от выраженности дефицита тестостерона и генетических факторов. В то же время наибольшие риски, согласно имеющимся на сегодняшний день данным, были отмечены у мужчин старше 60-65 лет.
Полный текст
Об авторах
С. С Апетов
ООО «Центр эндокринного здоровья»
Email: apetov@rambler.ru
к.м.н., врач-эндокринолог, акушер-гинеколог Челябинск, Россия
В. В Апетова
ООО «Центр эндокринного здоровья»Челябинск, Россия
Список литературы
- Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-doi: 10.1056/NEJMoa1000485.
- Vigen R., O'Donnell C.I., Baron A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-doi: 10.1001/jama.2013.280386. Erratum in: JAMA. 2014 Mar 5;311(9):967.
- Finkle W.D., Greenland S., Ridgeway G.K., et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi: 10.1371/journal.pone.0085805.
- Baillargeon J., Kuo Y.F., Westra J.R., et al. Testosterone Prescribing in the United States, 2002-2016. JAMA. 2018;320(2):2002. doi: 10.1001/jama.
- Cheetham T.C., An J., Jacobsen S.J., et al. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency. JAMA.Intern Med. 2017;177(4):491-99. Doi: 10.1001/ jamainternmed.22018.7999.
- Shores M.M. Testosterone treatment and cardiovascular events in prescription database studies. Asian J Androl. 2018;20(2):138-44. doi: 10.4103/aja.aja_25_17.
- Pantalone K.M., George J., Ji X., et al. Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality. Basic Clin Androl. 2019;29:5. doi: 10.1186/s12610-019-0085-7.
- Shores M.M., Smith N.L., Forsberg C.W., et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-58. doi: 10.1210/jc.2011-2591.
- Loo S.Y., Azoulay L., Nie R., et al. Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study. Am J Med. 2019;132(9): 1069-77.e4. Doi: 10.1016/j. amjmed.2(019.03.022.
- Beral V., Gaitskell K., et al. Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835-42. Doi: 10.1016/ S0140-6736(14)61687-1.
- Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi: 10.1001/jama.288.3.321.
- Rossouw J.E, Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. doi: 10.1001/jama.297.13.1465. Erratum in: JAMA. 2008;299(12):1426.
- Manson J.E, Aragaki A.K., Rossouw J.E., et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-38. Doi: 10.1001/ jama.2017.11217.
- Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am. J. Epidemiol. 2007;166(5):506-10. doi: 10.1093/aje/ kwm214.
- Hodis H.N., Collins P., Mack W.J., et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;15(3):217-28. doi: 10.3109/13697137.2012.656401.
- ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update. 2006;12(5):483-97. Doi: 10.1093/ humupd/dml028.
- Gao Z, Chen Z., Sun A., et al. Gender differences in cardiovascular disease. Med Nov Tech Dev. 2019;(4):100025.
- Kapoor D, Jones T.H. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging. 2008;25:357-69.
- Kupelian V, Hayes F.J., Link C.L., et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab. 2008;93(9):3403-10. doi: 10.1210/jc.2008- 0054.
- Hackett G. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sex Med Rev. 2019;7(3):476-90. doi: 10.1016/j.sxmr.2018.12.004.
- Jones T.H. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496-503. Doi: 10.1016/j. tem.2010.03.002.
- Webb C.M., Collins P Role of Testosterone in the Treatment of Cardiovascular Disease. Eur Cardiol. 2017;12(2):83-7. Doi: 10.15420/ ecr.2017:21:1.
- Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694-701. doi: 10.1161/CIRCULATI0NAHA.107.719005.
- Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68-75. doi: 10.1210/jc.2007-1792.
- Akishita M., Hashimoto M., Ohike Y, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210(1):232-36. doi: 10.1016/j.atherosclerosis.2009.10.037.
- Holmegard H.N., Nordestgaard B.G., Jensen G.B., et al. Sex Hormones and Ischemic Stroke: A Prospective Cohort Study and Meta-Analyses. J Clin Endocrinol Metab. 2016;101(1):69-78. doi: 10.1210/jc.2015-2687.
- Corona G., Rastrelli G., Di Pasquale G., et al. Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. J Sex Med. 2018;15(9):1260-71. Doi: 10.1016/j. jsxm.2018.06.012.
- Shores M.M., Biggs M.L., Arnold A.M., et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061-68. Doi: 10.1210/ jc.2013-3576.
- Haring R., Teng Z., Xanthakis V., et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol. (Oxf). 2013;78(4):629-34. doi: 10.1111/cen.12013.
- Collet T.H., Ewing S.K., Ensrud K.E., et al. Endogenous Testosterone Levels and the Risk of Incident Cardiovascular Events in Elderly Men: The MrOS Prospective Study. J Endocr Soc. 2020;4(5):bvaa038. doi: 10.1210/jendso/ bvaa038.
- Luo S., Yeung Sh.L.A., Zhao J.V., et al. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. BMJ. 2019;364:1476. Doi: 10.1136/ bmj.l476.
- Holmegard H.N., Nordestgaard B.G., Schnohr P., et al. Endogenous sex hormones and risk of venous thromboembolism in women and men. J Thromb Haemost. 2014;12(3):297-305. doi: 10.1111/jth.12484.
- Roetker N.S., MacLehose R.F., Hoogeveen R.C., et al. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thromb Haemost. 2018;118(11):1940-50. doi: 10.1055/s-0038-1673613.
- Soisson V., Brailly-Tabard S., Helmer C., et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75(3):282-8. Doi: 10.1016/j. maturitas.2013.04.012.
- Yeap B.B. Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular events in men. Asian J Androl. 2018;20(2):109-14. doi: 10.4103/aja. aja_50_17.
- Yeap B.B., Alfonso H., Chubb S.A., et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99(1):E9-18. doi: 10.1210/jc.2013-3272.
- Wallis C.J., Lo K., Lee Y., et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet. Diab Endocrinol. 2016;4(6):498-506. Doi: 10.1016/ S2213-8587(16)00112-1.
- Hackett G.I., Ramachandran S., Strange R., et al. Statin, testosterone and PDE5Is and age-related mortality in type 2 diabetes. World J Diab. 2017;8:104-11. doi: 10.4239/wjd.v8.i3.104.
- Hackett G., Heald A.H., Sinclair A., et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins.Int J Clin Pract. 2016;70:244-53. doi: 10.1111/ijcp.12779.
- Baillargeon J., Urban R.J., Kuo Y.F., et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother. 2014;48(9):1138-44. doi: 10.1177/1060028014539918.
- Saad F., Yassin A., Haider A., et al. Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. Korean J Urol. 2015;56(4):310-doi: 10.4111/kju.2015.56.4.310.
- Snyder P.J., Bhasin S., Cunningham G.R., et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-24. doi: 10.1056/NEJMoa1506119.
- Alexander G.C., Iyer G., Lucas E., et al. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and MetaAnalysis. Am J Med. 2017;130(3):293-305. doi: 10.1016/j.amjmed.2016.09.017.
- Qeseem A., Horwitch C.A., Vijan S., et al. Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American College of Physicians. Ann Intern Med. 2020;172:126-33. doi: 10.7326/M19-0882.
- Baillargeon J., Urban R.J., Morgentaler A., et al. Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clin Proc. 2015;90:1038-45. Doi: 10.1016/j. mayocp.o0l5.05.012.
- Sharma R., Oni O.A., Chen G., et al. Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism: A Retrospective Cohort Study of the Veterans Administration Database. Chest. 2016;150(3):563-71. Doi: 10.1016/j. chest.2016.05.007.
- Li H, Benoit K., Wang W, et al. Association between Use of Exogenous Testosterone Therapy and Risk of Venous Thrombotic Events among Exogenous Testosterone Treated and Untreated Men with Hypogonadism. J Urol. 2016;195(4 Pt.:1065- 72. doi: 10.1016/j.juro.2015.10.134.
- Martinez C., Suissa S., Rietbrock S., et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016;355:i5968. Doi: 10.1136/ bmj.i5968.
- Walker R.F, Zakai N.A., MacLehose R.F, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA.Intern Med. 2020;180(2):190-97. Doi: 10.1001/ ]amaioternmed.0Q1-.535.
- Otsuke F, Yesude S., Noguchi T, et al. Pathology of coronary atherosclerosis and thrombosis. Cardiovasc Diagn Ther. 2016;6(4):396-408. doi: 10.21037/cdt.2016.06.01.
- Budoff M.J., Ellenberg S.S., Lewis C.E., et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708-16. doi: 10.1001/jama.2016.21043.
- Beserie S, Harman S.M., Trevison T.G., et al. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. JAMA. 2015;314(6):570-81. Doi: 10.1001/ jama.2015.8881.
- Drinke P.J, Jochen A.L., Cuisinier M., et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc. 1995;43:899-901. doi: 10.1111/j.1532-5415.1995.tb05534.x.
- Chehle E.J., Hayek M.E., Morley J.E. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male. 2011;14(2):83-90. doi: 10.3109/13685538.2010.541538.
- Vermeulen A., Kaufman J.M., Goemeere S., et al. Estradiol in elderly men. Aging Male. 2002;5(2):98-102.
- Clelend W.H., Mendelson C.R., Simpson E.R. Aromatase activity of membrane fractions of human adipose tissue stromal cells and adipocytes. Endocrinol. 1983;113(6):2155-60.
- Schneider G., Kirschner M.A., Berkowitz R., et al. Increased estrogen production in obese men. J Clin Endocrinol Metab. 1979;48(4):633-38. doi: 10.1210/jcem-48-4-633.
- Swerdloff R.S., Wang C., Cunningham G., et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonedel men. JClin. Endocrinol Metab. 2000;85(12):4500-10. doi: 10.1210/jcem.85.12.7045.
- Bang A.K., Jergensen N., Rejpert-De Meyts E, et al. UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecenoete. A Retrospective Experience from 207 Men with Hypogonadism. Front. Endocrinol. (Lausanne). 2013;4:94. doi: 10.3389/fendo.2013.00094.
- Wrenicz J.K., Cygenkiewicz I., Rosiek M., et al. The relationship between sex hormones and lipid profile in men with coronary artery disease.Int J Cardiol. 2005;101(1):105-10. Doi: 10.1016/j. ijcard.2004.07.010.
- Tivesten A., Hulthe J., Wallenfeldt K., et al. Circulating Estradiol Is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men. J Clin Endocrinol Metab. 2006;91:4433-7. Doi: 10.1210/ jc.2006-0932.
- Abbott R.D., Leuner L.J., Rodriguez B.L., et al. Serum estradiol and risk of stroke in elderly men. Neurol. 2007;68(8):563-68. doi: 10.1212/01. wnl.00002544 73.88647.ca.
- Tripethi Y., Hegde M. Serum estradiol and testosterone levels following acute myocardial infarction in men. Ind J Physiol Pharmacol. 1998;49:291-94.
- Mohamad M.J., Mohammad M.A., Kareyyem M., et al. Serum levels of sex hormones in men with acute myocardial infarction. Neur Endocrinol Lett. 2005;28{2):122585.
- Aperne R.R., Rejesweri D.R., Remelingem K., et al. Estradiol and lipid levels in men with acute myocardial infarction.Int J Res Med Sci. 2020;8:989-92.
- Lekshmen K.M., Kaplan B., Trevison T.G., et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010;95(8):3955-69. doi: 10.1210/jc.2010-0102.
- Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2009;89(2):503-10. doi: 10.1210/jc.2003-031110.
- Schubert M, Minnemenn T., Hubler D., et al.Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. -009;84(11):59-4-39. Doi: 10.1210/ jc.2009-0897.
- Jenkowske E.A., Rozentryt P., Ponikowske B, et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301(18):1892-901. Doi: 10.1001/ jama1.2009.639.
- Renoux C., DellAniello S., Brenner B, et al. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiol. Drug Saf. -017;-6(5):559-60. Doi: 10.1002/ pds.4197.
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;396(8990):1575-82.
- Spitzer W.O. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation. J. Obstet. Gynaecol. Can. 2003;25(12):1011-doi: 10.1016/s1701-2163(16)30392-5.
- Dinger J.C., Heinemann L.A., Kuhl-Hebich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 192,975 women-yeers of observation. Contraception. 2007;75(5):399-59. doi: 10.1016/a.oontreoeption.2006.12.019.
- van Hylckeme Vlieg A., Helmerhorst F.M., Vendenbroucke J.P, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA cese-control study. BMJ. 2009;339:b2921. doi: 10.1136/bmj.b2921
- Bloemenkemp K.W., Rosendeel F.R., Helmerhorst F.M., et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160(1):99-52. Doi: 10.1001/ archinte.160.1.49.
- Glueck C.J., Goldenberg N., Wang P. Thromboembolism peaking 3 months after starting testosterone therapy: testosterone-thrombophilia interactions. J Investig Med. ;66(4):733-38. doi: 10.1136/jim-2017-000637.
- Sandset P.M, H0ibraaten E., Eilertsen A.L., et al. Mechanisms of thrombosis related to hormone therapy. Thromb Res. 2009;123(Suppl. :S70-73. doi: 10.1016/S0049-3848(09) 70015-5.
- Costello B.T, Sprung K., Coulter S.A. The Rise and Fall of Estrogen Therapy: Is Testosterone for «Manopause» Next? Tex Heart Inst J. 2017;44(5):338-40. doi: 10.14503/THIJ-17-6360.
- Shoskes J.J., Wilson M.K., Spinner M.L. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-43. doi: 10.21037/tau.2016.07.10.
- Layton J.B., Meier C.R., Sharpless J.L., et al.Comparative Safety of Testosterone Dosage Forms. JAMA.Intern Med. 2015;175(7):1187-96. doi: 10.1001/jamainternmed.2015.1573. Erratum in: JAMA Intern Med. 2015;175(7):1248.
- Borst S.E., Yarrow J.F. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. Am J Physiol Endocrinol Metab. 2015;308(12):E1035-42. Doi: 0.1152/ ajpendo.001 11.2015.
- Sharma R., Oni O.A., Gupta K., et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706-15. doi: 10.1093/eurheartj/ehv346.
- Oni O.A., Dehkordi S.H.H., Jazayeri M.A., et al. Relation of Testosterone Normalization to Mortality and Myocardial Infarction in Men With Previous Myocardial Infarction. Am J Cardiol. 2019;124(8):1171-78. Doi: 10.1016/j. amjcard.2019.07.019.
- Mulhall J.P., Trost L.W., Brannigan R.E., et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-32. Doi: 10.1016/j. juro.2018.03.115.
- Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-59. Doi: 10.1210/ jc.2009-2354.
- Khera M., Broderick G.A., Carson C.C., et al. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016;91(7):908-26. doi: 10.1016/j. mayocp.20016.04.022.
- Stepaniak U., Szafraniec K., Kubinova R., et al. Age at natural menopause in three central and eastern European urban populations: the HAPIEE study Maturitas. 2013;75(1):87-93. Doi: 10.1016/j. maturitas.2013.02.008.
- Bhasin S., Brito J.P., Cunningham G.R., et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-44. doi: 10.1210/jc.2018-00229.